Educational purposes only. Not medical advice.

Many adolescents treated for major depressive disorder (MDD) continue to experience residual symptoms even after taking antidepressant medication. Selective serotonin reuptake inhibitors (SSRIs) are standard therapy, but they are not fully effective for every patient. Several studies have noted that people with depression often have lower levels of DHA, an omega-3 fatty acid that plays a key role in brain structure and function.

A study published in PharmaNutrition explored whether omega-3 supplementation might help adolescents who still had symptoms despite being medicated.[1] This was an open-label trial, meaning both participants and researchers knew who was receiving treatment.

What the Study Found

The researchers first observed that DHA levels were significantly lower in the depressed adolescents compared to healthy controls. Participants were then given either:

  • High-dose omega-3: 16.2 g/day

  • Low-dose omega-3: 2.4 g/day

Results

  • 40% of the low-dose group achieved remission

  • 100% of the high-dose group achieved remission

The study was small and not blinded, so the results are considered preliminary, but the findings were notable. The researchers also emphasized that omega-3 supplementation was well tolerated, making it an appealing area for further research in adolescents who continue to struggle with symptoms despite SSRI therapy. Click for more on depression and omega-3 fatty acids.

  1. PharmaNutrition (2014 April 1; 2(2): 38-46) Detection and Treatment of Long-Chain Omega-3 Fatty Acid Deficiency in Adolescents with SSRI-Resistant Major Depressive Disorder